235 related articles for article (PubMed ID: 20063038)
1. Identification and characterization of new functional truncated variants of somatostatin receptor subtype 5 in rodents.
Córdoba-Chacón J; Gahete MD; Duran-Prado M; Pozo-Salas AI; Malagón MM; Gracia-Navarro F; Kineman RD; Luque RM; Castaño JP
Cell Mol Life Sci; 2010 Apr; 67(7):1147-63. PubMed ID: 20063038
[TBL] [Abstract][Full Text] [Related]
2. Identification and characterization of two novel truncated but functional isoforms of the somatostatin receptor subtype 5 differentially present in pituitary tumors.
Durán-Prado M; Gahete MD; Martínez-Fuentes AJ; Luque RM; Quintero A; Webb SM; Benito-López P; Leal A; Schulz S; Gracia-Navarro F; Malagón MM; Castaño JP
J Clin Endocrinol Metab; 2009 Jul; 94(7):2634-43. PubMed ID: 19401364
[TBL] [Abstract][Full Text] [Related]
3. Truncated variants of pig somatostatin receptor subtype 5 (sst5) act as dominant-negative modulators for sst2-mediated signaling.
Durán-Prado M; Gahete MD; Delgado-Niebla E; Martínez-Fuentes AJ; Vázquez-Martínez R; García-Navarro S; Gracia-Navarro F; Malagon MM; Luque RM; Castaño JP
Am J Physiol Endocrinol Metab; 2012 Dec; 303(11):E1325-34. PubMed ID: 23032684
[TBL] [Abstract][Full Text] [Related]
4. Homologous and heterologous in vitro regulation of pig pituitary somatostatin receptor subtypes, sst1, sst2 and sst5 mRNA.
Luque RM; Park S; Peng XD; Delgado E; Gracia-Navarro F; Kineman RD; Malagón MM; Castaño JP
J Mol Endocrinol; 2004 Apr; 32(2):437-48. PubMed ID: 15072550
[TBL] [Abstract][Full Text] [Related]
5. Truncated somatostatin receptors as new players in somatostatin-cortistatin pathophysiology.
Córdoba-Chacón J; Gahete MD; Durán-Prado M; Luque RM; Castaño JP
Ann N Y Acad Sci; 2011 Mar; 1220():6-15. PubMed ID: 21388399
[TBL] [Abstract][Full Text] [Related]
6. Porcine somatostatin receptor 2 displays typical pharmacological sst2 features but unique dynamics of homodimerization and internalization.
Durán-Prado M; Bucharles C; Gonzalez BJ; Vázquez-Martínez R; Martínez-Fuentes AJ; García-Navarro S; Rhodes SJ; Vaudry H; Malagón MM; Castaño JP
Endocrinology; 2007 Jan; 148(1):411-21. PubMed ID: 17053026
[TBL] [Abstract][Full Text] [Related]
7. Characterization of intracellular signaling mediated by human somatostatin receptor 5: role of the DRY motif and the third intracellular loop.
Peverelli E; Lania AG; Mantovani G; Beck-Peccoz P; Spada A
Endocrinology; 2009 Jul; 150(7):3169-76. PubMed ID: 19342453
[TBL] [Abstract][Full Text] [Related]
8. The third intracellular loop of the human somatostatin receptor 5 is crucial for arrestin binding and receptor internalization after somatostatin stimulation.
Peverelli E; Mantovani G; Calebiro D; Doni A; Bondioni S; Lania A; Beck-Peccoz P; Spada A
Mol Endocrinol; 2008 Mar; 22(3):676-88. PubMed ID: 18096696
[TBL] [Abstract][Full Text] [Related]
9. Highly potent and subtype selective ligands derived by N-methyl scan of a somatostatin antagonist.
Rajeswaran WG; Hocart SJ; Murphy WA; Taylor JE; Coy DH
J Med Chem; 2001 Apr; 44(8):1305-11. PubMed ID: 11312929
[TBL] [Abstract][Full Text] [Related]
10. Modulation of pituitary somatostatin receptor subtype (sst1-5) messenger ribonucleic acid levels by changes in the growth hormone axis.
Park S; Kamegai J; Johnson TA; Frohman LA; Kineman RD
Endocrinology; 2000 Oct; 141(10):3556-63. PubMed ID: 11014208
[TBL] [Abstract][Full Text] [Related]
11. Octreotide and pasireotide (dis)similarly inhibit pituitary tumor cells in vitro.
Ibáñez-Costa A; Rivero-Cortés E; Vázquez-Borrego MC; Gahete MD; Jiménez-Reina L; Venegas-Moreno E; de la Riva A; Arráez MÁ; González-Molero I; Schmid HA; Maraver-Selfa S; Gavilán-Villarejo I; García-Arnés JA; Japón MA; Soto-Moreno A; Gálvez MA; Luque RM; Castaño JP
J Endocrinol; 2016 Nov; 231(2):135-145. PubMed ID: 27587848
[TBL] [Abstract][Full Text] [Related]
12. A potential inhibitory role for the new truncated variant of somatostatin receptor 5, sst5TMD4, in pituitary adenomas poorly responsive to somatostatin analogs.
Durán-Prado M; Saveanu A; Luque RM; Gahete MD; Gracia-Navarro F; Jaquet P; Dufour H; Malagón MM; Culler MD; Barlier A; Castaño JP
J Clin Endocrinol Metab; 2010 May; 95(5):2497-502. PubMed ID: 20233783
[TBL] [Abstract][Full Text] [Related]
13. Activation of adenylate cyclase by human recombinant sst5 receptors expressed in CHO-K1 cells and involvement of Galphas proteins.
Carruthers AM; Warner AJ; Michel AD; Feniuk W; Humphrey PP
Br J Pharmacol; 1999 Mar; 126(5):1221-9. PubMed ID: 10205012
[TBL] [Abstract][Full Text] [Related]
14. Somatostatin and its receptors contribute in a tissue-specific manner to the sex-dependent metabolic (fed/fasting) control of growth hormone axis in mice.
Córdoba-Chacón J; Gahete MD; Castaño JP; Kineman RD; Luque RM
Am J Physiol Endocrinol Metab; 2011 Jan; 300(1):E46-54. PubMed ID: 20943754
[TBL] [Abstract][Full Text] [Related]
15. Selective regulation of somatostatin receptor subtype signaling: evidence for constitutive receptor activation.
Ben-Shlomo A; Pichurin O; Barshop NJ; Wawrowsky KA; Taylor J; Culler MD; Chesnokova V; Liu NA; Melmed S
Mol Endocrinol; 2007 Oct; 21(10):2565-78. PubMed ID: 17609435
[TBL] [Abstract][Full Text] [Related]
16. Internalization of sst2, sst3, and sst5 receptors: effects of somatostatin agonists and antagonists.
Cescato R; Schulz S; Waser B; Eltschinger V; Rivier JE; Wester HJ; Culler M; Ginj M; Liu Q; Schonbrunn A; Reubi JC
J Nucl Med; 2006 Mar; 47(3):502-11. PubMed ID: 16513620
[TBL] [Abstract][Full Text] [Related]
17. Role of glucocorticoids in the regulation of pituitary somatostatin receptor subtype (sst1-sst5) mRNA levels: evidence for direct and somatostatin-mediated effects.
Park S; Kamegai J; Kineman RD
Neuroendocrinology; 2003 Sep; 78(3):163-75. PubMed ID: 14512709
[TBL] [Abstract][Full Text] [Related]
18. Expression and localisation of somatostatin receptor subtypes sst1-sst5 in areas of the rat medulla oblongata involved in autonomic regulation.
Spary EJ; Maqbool A; Batten TF
J Chem Neuroanat; 2008 Jan; 35(1):49-66. PubMed ID: 17646081
[TBL] [Abstract][Full Text] [Related]
19. Differential ligand-mediated pituitary somatostatin receptor subtype signaling: implications for corticotroph tumor therapy.
Ben-Shlomo A; Schmid H; Wawrowsky K; Pichurin O; Hubina E; Chesnokova V; Liu NA; Culler M; Melmed S
J Clin Endocrinol Metab; 2009 Nov; 94(11):4342-50. PubMed ID: 19820006
[TBL] [Abstract][Full Text] [Related]
20. Characterisation of human recombinant somatostatin receptors. 1. Radioligand binding studies.
Siehler S; Seuwen K; Hoyer D
Naunyn Schmiedebergs Arch Pharmacol; 1999 Nov; 360(5):488-99. PubMed ID: 10598788
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
